Previous Statements by MYGN
» Myriad Genetics Inc. F2Q10 Earnings Conference Call
» Myriad Genetics, Inc F4Q09 (Qtr End 06/30/09) Earnings Call Transcript
» Myriad Genetics F3Q09 (Qtr End 03/31/09) Earnings Call Transcript
The Dublin firm announced an offering of $500 million of exchangeable senior notes due 2024.
Myriad Genetics, Spectrum Pharmaceuticals and Array BioPharma were among the biotech stock movers in early trading on Wednesday.
Sage Therapeutics, Immunomedics and Myriad Genetics were among the premarket biotech stock movers on Monday.
Cramer points to Gilead's pipeline for its problems.